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Abstract
Through this paper, we have attempted to model the demand for di¤er-
ent classes of antibiotics used for respiratory infections in outpatient care in
Switzerland using a spatial version of the linear approximate Almost Ideal
Demand System (AIDS) model. This model takes spatial dependency into
account by means of spatial lags of antibiotic budget shares. We control for
the health status of patients and the potential harmful e¤ects of antibiotic use
in terms of bacterial resistance. Elasticities to socioeconomic determinants of
consumption and own- and cross-price elasticities between di¤erent groups
of antibiotic have salso been computed in this paper. Signicant cross-price
elasticities are found between newer or more expensive generations and older
or less expensive generations of antibiotics.
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1 Introduction
Antibiotics di¤er from other pharmaceutical products in several ways (Ellison and
Hellerstein, 1999). They are generally prescribed by doctors because of their phar-
macological characteristics. Consequently, the patientspreferences for specic ther-
apeutic components may be of little relevance. At the same time, aspects such as
the price may play an important role if the consumer was to bear a substantial share
of the cost of drugs directly.
In primary care, doctors may face a rst trade-o¤between prescribing and delay-
ing an antibiotic therapy because of uncertainty of the nature of a patients infection
(viral or bacterial). Although antibiotic therapy is not e¤ective against common vi-
ral infections, expected cost savings (in terms of time and troubles) in the case of
bacterial infections may overcome the expected social loss from bacterial resistance.
From the economic point of view, bacterial resistance accounts for relevant external
e¤ects. First, several antibiotic therapies might be prescribed before nding the
e¤ective one, which leads to income loss or possibly premature deaths. Second, the
reduced e¤ectiveness of drugs increases social costs to produce new generations of
pharmaceutical components.
A second trade-o¤ is observed between prescribing broad spectrum and narrow
spectrum antibiotics. Although the intensive use of broad spectrum components,
which are generally more expensive, reduces uncertainty in the outcome of the treat-
ment, this may generate higher levels of bacterial resistance. It has been argued
that the persistent use of one type of antibiotics may be sub-optimal for the society.
Literature suggests that the negative externality of resistance can be reduced by
changing the type of antibiotic used (Ellison and Hellerstein 1999; Laxminarayan
and Weitzman, 2002; Rowthorn and Brown, 2003), since the same type of bacteria
may be susceptible to more than one antibiotic component.1
1Increasing rates of Streptococcus pneumoniae strains resistant to penicillin has led to the use
of macrolides. However, the clinical e¤ectiveness of the latter category has also begun to decrease
(Alvarez-Elcoros and Enzler, 1999). The analysis by Ednie et al. (1996) suggests that in areas
where penicillin-resistant strains are common, the empirical antibiotherapy using macrolides should
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Regional heterogeneity in the mix of antibiotics used has been recently observed
within the countries (Filippini et al., 2006; Kern et al., 2006). This may indicate
that some antibiotic components are preferred by local physicians and patients,
which raises the issue of optimal use at the local level. The rise of resistant organ-
isms in a particular region can force physicians to face constraints of e¤ectiveness
when substituting existing types of antibiotics with newer and more e¤ective ones.2
Furthermore, there are other factors that inuence the mix of antibiotics such as
di¤erences in attitudes towards the same type of antibiotic, patientscharacteristics,
antibiotic price and economic incentives.
This study focuses on factors a¤ecting the local mix of main antibiotics categories
in Switzerland, in particular the e¤ect of prices. The demand for specic antibiotic
groups has been investigated in studies by Ellison et al. (1997) and Chaudhuri et
al. (2003). The focus is on the structure of the demand for two segments of the
market: cephalosporins and quinolones. Demand is modelled in two stages. Firstly
a substance is singled out from among a set of substances; then, a brand/generic
version of the product is chosen. This approach is suitable for the analysis of specic
categories of antibiotics since the substances constitute close therapeutic substitutes
and may be similar in terms of the impact of bacterial resistance. The model relies
on the hypothesis that physician and patient decisions within a given antibiotic
category do not depend on the availability of alternative categories but are based
on the specic names of substances. We argue, however, that this scenario may
not reect the patients and doctors view correctly. Indeed, doctors and patients
tend to be concerned with the e¤ectiveness of broad categories of antibiotics, each
including a set of active ingredients with similar characteristics and, for this reason,
likely to be di¤erently a¤ected by bacterial resistance. Individuals may then choose
from among a limited set of antibiotic types clustered according to common practice
and shared beliefs regarding their e¤ectiveness.
then be changed.
2The resistance-induced antibiotic substitution has been recently addressed by Howard (2004)
among others.
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This paper intends to investigate the structure of the demand for antibiotics used
for respiratory infections by modelling the decision process of rational patients.3 We
are interested in the price and income sensibility of di¤erent antibiotic categories.
Understanding the determinants of antibiotic treatment practices is necessary to
reduce antibiotic misuse and the cost of bacterial resistance. Our ndings may
drive more e¤ective policies to improve the e¢ cient use of the antibiotics in the
community. It has been assessed that the expected benets of policy interventions
aimed at reducing the misuse of antibiotics in Switzerland is around e6:8 M per
year (Filippini et al., 2009). Appropriate incentives a¤ecting antibiotic consumption
and, consequently, levels of bacterial resistance can be designed by policy makers
by looking at the price and income sensibility of di¤erent antibiotic groups in our
model. Since the large use of broad spectrum antibiotics and/or the persistent use of
one type of antibiotics may exacerbate the threat of bacterial resistance, information
on price sensibility may be useful. For instance, when implementing policies based
upon a tax/subsidy mechanism in addition to information campaigns targeted at
consumers and health care providers.
Similar to Ellison et al. (1997) and Chaudhuri et al. (2003), we model antibiotic
demand as a multistage budgeting problem but with a wider set of substances,
those that can be prescribed for common respiratory infections in outpatient care.
Outpatient antibiotics are then aggregated in four groups according to what are
plausible alternatives in the treatment of respiratory infections (classic penicillins,
penicillins amoxi/clav plus 1st and 2nd generations of cephalosporins, 3rd generation
of cephalosporins and quinolones, macrolides).4
We analyse the allocation of antibiotic expenditure across antibiotic groups us-
3We are aware that patients take decisions about antibiotic use under doctors advice. However,
as suggested by several studies, e.g. Cockburn and Pit (1997), physiciansdecisions are inuenced
by patients preferences and we can plausibly assume that the nal decision about consumption is
made by the patient.
4Most of the antibiotics used in outpatient care are for the treatment of respiratory infections
(Blasi et al., 2006; Gonzalves et al., 2001). We focus on this category and exclude antibiotics
that are used for other types of infections. Hence, our categories include all plausible therapeutic
substitutes.
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ing the Almost Ideal Demand System (AIDS) specication proposed by Deaton and
Muellbauer (1980). The AIDS model is commonly used to estimate price and income
elasticities of the demand for goods when expenditure share data are available.5 We
compute own- and cross-price elasticities between old and new generations of an-
tibiotics and between antibiotics that are di¤erently a¤ected by bacterial resistance
using data from small geographic areas in Switzerland. We also estimate conditional
expenditure elasticities and marginal expenditure shares for each group of antibi-
otics. The AIDS model is estimated using a relatively new econometric approach
that also considers the problem of spatial autocorrelation.
The structure of the article is as follows. Section 2 sketches the application of
the linear approximate AIDS model to the demand of antibiotics and discusses some
testable hypothesis. Section 3 presents the data and summarizes the variables used
in the model. Section 4 gives some analyses and results. And section 5 concludes
the paper.
2 The model
To sketch the demand for antibiotics in outpatient care we build on the AIDS model
and extend the approach to include spatial aspects of consumption. We hypothesize
that the individual utility derived from the use of antibiotics is weakly separable
from quantities of all other types of goods consumed. Consequently, consumers
follow a multistage process to allocate their budget to antibacterial products. In
the rst stage, the total spending is allocated to broad categories of goods such as
health care versus other types of goods or services. The health care spending is
then separated in subgroups such as pharmaceuticals, diagnostic tests and inpatient
care. Given the nature of the infection, the budget share for pharmaceuticals is
5Ma and al. (2004) estimated the share equations of animal product consumption for Chinese
households. Combining the AIDS model and the two-stage Heckman procedure, Lazaridis (2004)
focused on the factors a¤ecting the demand for di¤erent types of oils and fats in Greece. Boetel
and Liu (2003) estimated a meat demand system and investigated the e¤ect of food information
on the meat shares consumed.
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assigned to antibiotics and other types of drugs. Finally, the choice is between
di¤erent categories of antibiotics according to their therapeutic attributes, the risks
of bacterial resistance, and the cost of treatment.6
The individual expenditure function derived from the consumer theory is aggre-
gated across individuals to obtain the antibiotic expenditure in the local market
area.7 Muellbauer (1975, 1976) showed that exact aggregation is possible within a
specic family of preferences. These preferences are known as the price independent
generalized logarithmic (PIGLOG) class of preferences. The PIGLOG class can be
denoted by the following expenditure function, which is the minimum expenditure
necessary to achieve a certain level of utility at any given price
log c(u; p) = (1  u) log a(p) + u log b(p), (1)
where u is the level of utility, a(p) and b(p) represent functions of a price vector p.
Following Deaton and Muellbauer (1980) we assume
log a(p) = 0 +
X
i
i log pi +
1
2
X
i
X
j
ij log pi log pj (2)
and
log b(p) = log a(p) + 0
Y
i
p
i
i , (3)
where 0; i; 0; i and ij are constants, and i and j are indexes representing dif-
ferent antibiotic categories.
6The Swiss National Research Programme on Antibiotic Resistance (NPR 49) reports that
information about the risk of bacterial resistance reach consumers mainly through the doctor
and information campaigns, since the other kind of information like newspapers are generally
inaccurate. Doctors are regularly informed by regional (cantonal) health authorities and through
their own experience of non-e¤ective treatments on their patients. Leaets are few and also not
widely distributed, although some cantonal hospitals deliver guidelines to practitioners in the area.
Consumers are generally aware that bacterial resistance a¤ecting some types of antibiotics may be
harmful although direct to consumers information is not satisfactory. Patients trust their doctors
for a correct understanding of the resistance problem.
7Aggregation theory provides the necessary conditions under which the aggregate demand, i.e.
the representation of market demand, can be treated as if it was the outcome of the decisions
of a rational representative consumer. See Muellbauer (1975) and Cornes (1992) for a general
discussion.
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Substituting for log a(p) and log b(p) in Eq. (1) we can write the cost function as
log c(u; p) = 0 +
X
i
i log pi +
1
2
X
i
X
j
ij log pi log pj + 0u
Y
i
p
i
i , (4)
which is linearly homogeneous in prices, provided that the following restrictions on
the parameters holdX
i
i = 1,
X
i
ij =
X
j
ij = 0,
X
i
i = 0. (5)
By applying the Shephards lemma8 and substituting afterwards the indirect
utility function9 derived from Eq. (2) we obtain the expenditure share of the ith
group of antibiotic substances
wi = i +
X
j
ij log pj + i log(x=P ), (6)
where x is the total expenditure for antibiotics in outpatient care10, P is a price
index dened by
logP = 0 +
X
i
i log pi +
1
2
X
i
X
j
ij log pi log pj (7)
and
ij =
1
2
(ij + ji). (8)
The following restrictions are implied by (5) and (8)X
i
ij =
X
j
ij = 0, ij = ji 8 i; j (i 6= j). (9)
8Demand functions in budget share form are derived from a natural logarithmic di¤erentiation
of the expenditure function with respect to prices.
9Total expenditure x is equal to c(u; p) for a utility maximising consumer. Hence, c(u; p) can
be inverted to give u(p; x), the indirect utility function.
10We dene x =
P
i
piqi as the total expenditure on antibiotics for respiratory infections in
outpatient care, where pi and qi represent the price and the quantity for the ith group of antibiotics
by the representative consumer.
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Provided that Eqs. (5), (8) and (9) hold true, the equation (6) denes a system
of demand functions. These are homogeneous of degree zero in prices and total
expenditure and satisfy the Slutsky symmetry. The total expenditure is then given
by
P
wi = 1.
The interpretation of the demand share summarized by Eq. (6) is straightfor-
ward. Without any change in relative prices and expenditures, i.e. the second and
the third terms of the right-hand side of the equation, the budget shares of di¤erent
groups of antibiotics are constant. Changes in relative prices a¤ect the demand
share through the terms ij. These capture the e¤ect on the i
th budget share from
a 1% increase in the price of the jth category of goods, with x=P held constant.
Changes in real expenditure are taken into account by the parameter i, which is
assumed equal to zero.
The share equation also underlines some basic properties of the demand function.
Other things being equal, the expenditure share of each group of commodities is
inversely associated with its own price and is positively related to the price of other
goods. The expected sign of ii is then negative. On the other side, ij should
exhibit a positive sign for any i 6= j if goods are close substitutes.
2.1 Spatial dependency and other determinants
The demand for antibiotics may also be a¤ected by variables other than price that
account for expenditure shifts. For instance, the incidence of infections may imply
seasonal trends in the per capita consumption. The socioeconomic characteristics of
a population and other aspects of health care supply may also a¤ect antibiotic use.
These aspects may be of little relevance in the demand share of di¤erent classes of
antibiotics, unless they shape preferences for specic antibiotic categories.
It has been suggested that the patients age signicantly a¤ects the route of
administration of antibiotics for lower respiratory tract infections (Mazzaglia et al.,
1999) and the type of antibiotic used (Pendergrast and Marrie, 1999). Moreover,
physicians may have an incentive to prescribe the newer and more expensive antibi-
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otics, that is ones with a broader spectrum of activity, which apparently reduces
risks for patients. Our model can be easily modied to account for expenditure
shifts determined by the structure of the population and cultural di¤erences.11
Following Ray (1980) and Pollak and Wales (1992), we extend our model to
include the additional determinants by a log-linear scaling procedure. Cultural
di¤erences across regions are taken into account by dummy variables.
From Eq. (6) the AIDS model can then be extended to analyse aggregate data
on antibiotic consumption across small geographic areas. Assuming separability
in quantities consumed for di¤erent types of goods, we can write the econometric
specication as
wi = i +
X
j
ij log pj + i log(x=P ) +
SX
k=1
ik log Vk +  i logH +
+i logRi +
TX
t=1
itDTt + iMwi + ui; (10)
where ik,  i, i, it and i are new parameters. The index i = 1; 2; 3; 4 denotes
four groups of antibiotic substances discussed later on in section 3 and summarized
in table 1.
From the econometric point of view, the choice of the appropriate method for
the estimation of Eq. (10) should consider the possibility of spatial autocorrela-
tion in antibiotic consumption. We found evidence of spatial autocorrelation using
the Morans I test. We then modied the extended AIDS model to take spatial
aspects into account. To our knowledge, the economic literature lacks extended
AIDS models with spatial e¤ects and the approach has not been previously applied
to the consumption of drugs.12 We introduced spatial lags of consumption in the
11Socioeconomic determinants of outpatient antibiotic use in Switzerland have been investigated
in previous studies by Filippini et al. (2006, 2009). The authors apply multivariate parametric
approaches to the aggregate demand of antibiotics but fail to investigate determinants of di¤erent
antibiotic groups.
12Spatial dependency in AIDS models has been applied, for instance, by Paraguas et al. (2006)
to investigate sh expenditure in the Philippines. The model, however, does not include socio-
economic factors as determinants of consumption.
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econometric specication following the spatial autoregressive parameter approach
proposed by Anselin (2001). We added spatial lags of consumption, iMwi, by
means of the spatial weight matrix M .13 The consumption of antibiotic group i
in one area is assumed to be a¤ected by the level of consumption in neighbouring
areas. Indeed, spatially adjacent areas may exhibit similar behaviour in terms of
antibiotic utilization due to inherent common spatial inuences.
The econometric specication in Eq. (10) includes a set of variables, Vk, that cap-
tures the demographic and cultural characteristics of the population. H is a proxy
for the health status of the population represented by the incidence of main bacterial
infections at the cantonal level, and Ri are indicators of bacterial resistance.14 The
magnitude of bacterial resistance country-wide and for macro regions is known to
doctors and patients, but such a gure is not broken down for smaller areas. We
operate on the plausible assumption that bacterial resistance varies across macro
regions rather than across smaller areas. However, given the information available,
the doctors as well as the patients attitude towards the risk perception of bacte-
rial resistance may di¤er across regions. Physicians and patients may then have a
heterogeneous attitudes towards the use of di¤erent types of antibiotics. Di¤erences
in the perception of the resistance problem may be related, for instance, to cultural
aspects included in Vk.
Finally, DTt (t = 1; ::; 3) are time dummies, and the random term ui is normally
13The modied version of the AIDS model that uses spatial lags is built on the structure of
Dynamic Almost Ideal Demand Systems. The way to introduce dynamic elements into the demand
system analysis is discussed, for instance, by Gracia et al. (1998) and Shukur (2002). The spatial
lag can be thought of as an "inertia lag" in the sense that consumers slowly adjust their consumption
behaviour with the neighbouring areas. Consequently, spatial dependency can be introduced by
means of an autoregressive specication in the demand system equations.
14 Indicators of bacterial resistance are dened as ratios between the number of non-susceptible
bacteria isolates over the number of tested isolates in regional laboratories and reported in regional
hospitals guidelines. We built ve types of indicators: susceptibility of Staphylococcus aureus
(SA), susceptibility of Streptococcus pneumoniae (SP), susceptibility of Escherichia coli (EC),
susceptibility of Campylobacter jejeuni (CJ) and susceptibility of all types of bacteria (ALL),
which is an average of the above indicators. Since each type of bacteria is tested against di¤erent
antibiotic substances, we built susceptibility indicators for each antibiotic group by averaging the
results of susceptibility tests to main substances in the group.
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and identically distributed with variance 2".
The expenditure share function is linearly homogeneous in all the explanatory
variables provided that the new parameters satisfy the following condition:X
i
ik =
X
i
 i =
X
i
i =
X
i
it =
X
i
i = 0, (11)
and P is approximated by the Stones geometric price index
logP =
X
i
wi log(pi): (12)
To avoid simultaneity problems, we use the median values of the expenditure
shares to calculate the Stone price index. Moreover, to reduce the risk of endogeneity
generated by the fact that prices of di¤erent groups of antibiotics are computed using
antibiotic shares, we consider lagged values for prices.
2.2 Expenditure and price elasticities
Since we are interested in studying the response of the demand for di¤erent antibiotic
groups to changes in price and expenditure, we calculate elasticities at the sample
mean of expenditure shares. Using Eqs. (10) and (12) we derive the uncompensated
(Marshallian) own-price elasticities ("ii) and cross-price elasticities ("ij) as15
"ii =  1 + ii
wi
  i; (13)
"ij =
ij
wi
  i
wj
wi
; i 6= j: (14)
Using the Slutsky equation, we then obtain the expenditure elasticity for the ith
antibiotic category given by
i = 1 +
i
wi
: (15)
A positive value suggests that good i is normal.
15See Alston et al. (1994) and Chalfant (1987) for details.
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The income compensated or net (Hicksian) own-price elasticities (ii) and cross-
price elasticities (ij) are obtained by applying the Slutsky decomposition to Eq.
(15) and using the price index in (12). These can be written as
ii =  1 + ii
wi
+ wi; (16)
ij =
ij
wi
+ wj; i 6= j: (17)
Consumer theory suggests that compensated own-price elasticities are negative
for normal goods. Moreover, if Eqs. (14) and (17) are positive the two groups of
antibiotics are cross substitutes, otherwise they are complements.
Using the Slutsky equation once again, it is possible to derive a relationship
between the compensated cross-price elasticities and expenditure elasticities: "ij =
wjij  wji, where ij are the partial elasticities of substitution, known also as the
Allen elasticities of substitution
ij = 1 +
ij
wiwj
i 6= j (18)
The sign of ij determines whether the goods i and j are complements or substitutes.
If ij is positive (negative) the two goods are substitutes (complements).
3 Data and variables
Our data covers 240 contiguous market areas that represent the entire Swiss terri-
tory. The areas exhibit a good degree of internal homogeneity in terms of population
density and providers of health care. Aggregate data on outpatient antibiotic sales of
di¤erent classes of antibiotics were provided by IHA-IMS Health Market Research.16
The dataset is detailed at product/brand name and data are available quarterly for
16Data on antibiotic sales derived from transactions between wholesalers and pharmacies and
physicians. Clearly, we are aware that the quantity of antibiotics sold and the quantity actually
consumed may di¤er. In this study we assume that patient non-compliance with doctors prescrip-
tion, if any, is a negligible factor. Finally, the potential mismatch between wholesale records and
prescribing data due to seasonal uctuations of retailers stocks is assumed to have only a limited
temporary e¤ect and is likewise ignored.
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2002. Since we focus on respiratory infections, we limited our analysis to the an-
tibiotics mainly used in the treatment of these diseases. However, part of these
antibiotics can also be used for the treatment of other types of infections like gas-
trointestinal infections. We aggregated active substances according to the antibiotic
class and the generation. Consequently, we kept 66% of the original dataset in terms
of sales. We excluded antibiotics with a parenteral route of administration. Four an-
tibiotic groups were identied (classic penicillins, penicillins amoxi/clav plus 1st and
2nd generation of cephalosporins, 3rd generation of cephalosporins and quinolones,
as well as macrolides) using the relevant literature on antibiotic treatments and
suggestions by experts. These groups are summarized in Table 1.
[Table 1: about here]
Penicillins are among the rst discovered antibiotics and have been largely used
against S. pneumoniae pathogens, which are a primary cause of respiratory tract
infections (Schito et al., 2000). In particular, classic penicillins (penicillins V, ampi-
cillin, amoxicillin) are commonly utilized to treat angina from streptococci and only
rarely for other types of respiratory infections. The rate of penicillin-resistance S.
pneumoniae has substantially increased since the mid-1980s (CDC, 1994).
Newer penicillins (amoxi/clav) can be combined with some cephalosporins since
they belong to the same broad classication (beta-lactams). The spectrum of am-
oxi/clav and 2nd generation of cephalosporins are very similar. Observed cross-
resistance between cephalosporins and penicillins may imply that patients infected
by penicillin-resistant bacteria are resistant to cephalosporins as well. The 1st gen-
eration of cephalosporins is currently of very little use.
The 3rd generation of cephalosporins has a broader activity spectrum compared
to the previous generations, which implies that it can be used against a larger variety
of bacteria. Consequently, it is suitable for more severe infections. Nevertheless, it
is generally used as an alternative to the 2nd generation. Practices may signicantly
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vary across the areas since some doctors are more likely than others to preserve the
3rd generation for more resistant bacteria.
Similarly, quinolones have a large range of antibacterial activity, which includes
multidrug resistant strains responsible for respiratory tract infections. Since this
category should also be used with caution and better preserved for more severe
cases, we considered it in a group together with the 3rd generation of cephalosporins.
When the nature of the infection is uncertain and doctors are quite risk averse, 3rd
generation of cephalosporins and quinolones may be preferred to penicillins and
other cephalosporins.
Finally, macrolides are generally known as an alternative to beta-lactams. In
some cases, bacterial resistance is more severe than for penicillins. Resistance
to macrolides has increased over time among penicillin-resistant pneumococci and
penicillin-susceptible strains. The preference for either penicillins or macrolides may
then depend upon established local practices and patients preferences.
Average prices of each antibiotic group have been imputed using expenditure
data and quantities. Quantities are measured in days of treatment (DOT) and
prices are consequently dened in currency units per one day of treatment. A daily
dose is standardised by the (WHO) World Health Organisation.
[Table 2: about here]
Table 2 gives summary statistics of expenditure shares and prices for the four
groups of antibiotics. Penicillins (amoxi/clav) and early generations of cephalosporins
and macrolides represent the largest shares of the expenditure. Note, however, that
strong di¤erences are observed across the areas. These categories may account for
only 15% of the total expenditure. On the other hand, in some areas they are largely
used and may reach a share of more than 70%.
Information on the other variables included in the model (see Table 3) are mainly
obtained from IHA-IMS . Demographic variables include the share of the population
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classied in ve ranges of age. Note, for instance, that individuals under 26 represent
less than 1% of the total population in some areas and more than 20% in others.
Similarly, the proportion of people between 60 and 74 largely varies across areas,
from 9:5% to almost 25%. French and Italian speaking areas represent 43:7% of
all areas and are generally characterized by a more intensive use of antibiotic per
capita. We dened a dummy variable that takes value equal to 1 if the area has a
Latin culture (French and Italian) and 0 otherwise.
[Table 3: about here]
The data on health status of patients is based on information on the incidence of
respiratory and common gastrointestinal diseases. As indicators we use the incidence
of S. pneumoniae infections, which represent the most common airborne bacterial
infections among the population. We alto take the incidence of Campylobacter and
Salmonella infections, which are a leading cause of gastrointestinal infections. The
reason for including data on gastrointestinal infections is that these data are gener-
ally more reliable than those for airborne bacterial infections because of availability
of information for all regions, larger sample, and reduced risk of bias.17 Although in
most cases a medical treatment is required to recover from these infections, patients,
especially children and old people, may be prescribed an antibiotic when symptoms
are particularly severe.
Finally, the magnitude of bacterial resistance is calculated for three macro re-
gions. There is a lack of resistance indicators for outpatient antibiotics covering the
Swiss territory. A systematic collection of data had not started until recently. How-
ever, regional hospital guidelines include a summary of resistance indicators and
are generally prepared every two years and are available to general practitioners.
The indicators are provided by regional laboratories that collect samples of bacteria
isolates from di¤erent settings like hospital wards and out of doors and test them
17Our information comes from yearly publications of the Swiss Federal Statistical O¢ ce at the
cantonal level.
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against several antibiotic substances. To construct our indicators we took the aver-
age result of tests for antibiotic substances representative of each antibiotic category
and published between 1999 and 2003. Following the SEARCH (Sentinel Surveil-
lance of Antibiotic Resistance in Switzerland) project standard, we considered three
macro regions: east, west and mid. Indicators for the three regions were then ob-
tained from main regional hospitals: Bern (mid), Geneva (west), Lugano (east),
and Zurich (east). Since Lugano and Zurich belong to the same region (east), we
averaged indicators from these hospitals guidelines to derive a resistance indicator
for the east region. Although the information on antibiotic resistance could be bro-
ken into smaller areas, we believe that this is one of the rst attempts to include
resistance indicators in econometric models of antibiotic consumption.18
In our regressions we test ve susceptibility indicators: Staphylococcus aureus, S.
pneumoniae, Escherichia coli, Campylobacter jejeuni, and a mix indicator (average
of the above indicators). In Table 3 we report the susceptibility of di¤erent antibiotic
groups to the S. pneumoniae which is used as an indicator in the basic specication
of the model. The reason is that S. pneumonie is more accurately related to respira-
tory infections than other bacteria and the impact of the combined indicator is not
signicantly di¤erent. The ranking between antibiotic groups in terms of bacterial
susceptibility is not straightforward since some types of bacteria are more likely to
be susceptible to specic antibiotic substances.19
18Local areas in Switzerland are by far smaller than geographical areas usually investigated in
many other countries. It is implausible that bacterial resistance varies signicantly across such
small areas. Health authorities are responsible for larger areas (cantons). Although we distinguish
between regionaland localinformation on bacterial resistance, the latter are neither available
nor are there plans to make them available in the near future. Clearly, there may be a margin
for improvement since we rely on information available for three macro areas which represent
an aggregation of cantons. However, some cantons are indeed very small and may not be able
to provide statistically signicant data for the surveillance system. For this reason, the sentinel
surveillance system collects and publishes resistance data for macro regions.
19Also for this reason we consider several resistance indicators. However, the estimation results
do not di¤er signicantly. In particular, estimations with susceptibility of Streptococcus pneumo-
niae and the average susceptibility to all bacteria exhibit very similar gures. The main results of
the model are also conrmed without resistance indicators.
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4 Estimation results
The spatial AIDS model dened by Eq. (10) is used to investigate the expenditure
shares of di¤erent groups of antibiotics. Explanatory variables include the price of
antibiotics, population characteristics like age structure and income and cultural
aspects, the incidence of community-acquired infections, and seasonal dummies. In
addition, the share of di¤erent antibiotic groups can be inuenced by the level of
bacterial resistance and antibiotic consumption in adjacent areas.
We estimate the model through the Zellners Iterative Seemingly Unrelated Re-
gression (SUR) procedure with the software STATA. The set of restrictions leads to a
singular residual variance/covariance matrix. Consequently, we drop one share equa-
tion from the system. This is the rst group (classic penicillins) which represents
the smallest budget share on average across the four groups. Using the estimated
parameters of the share equations of the other three groups and the restrictions
applied above, we then obtain the parameters for the dropped group.
The estimation results are reported in Table 4. Each equation is estimated
with 720 observations, since data for 240 areas are quarterly available, and one
quarter is excluded to allow for the use of lagged values for prices. The adjusted
R2 suggests that selected variables explain approximately 36%, 40% and 48% of
cross-area variations in the use of antibiotics, respectively for group 2 (penicillins
amoxi/clav and early generations of cephalosporins), group 3 (3rd generation of
cephaloporines and quinolones) and group 4 (macrolides).20
The estimated spatial autoregressive parameter associated with the lag term
DID i is signicant and positive.21
20The adjusted R2 reported in our estimations are satisfactory considering that the dataset is
dominated by cross-sectional variations, hence we are mainly explaining cross-sectional variation
in antibiotic consumption. For a general discussion of the interpretation of the R2 in AIDS models
see Verbeek (2008).
21The result suggests the evidence of consumption externalities across the areas. Higher con-
sumption of one group of antibiotics in one area is signicantly associated with higher consumption
of that group in adjacent areas. A plausible explanation for this result lies in the perceptions of
doctors and patients of the antibiotic group that is the most appropriate for the treatment of
common respiratory infections. Preferences may be a¤ected by practice styles in adjacent areas.
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[Table 4: about here]
The impact of consumer expenditure on the demand share of group 2 is negligible,
and negative for groups 3 and 4. Note, however, that the coe¢ cients are never
signicant. As detailed in Table 5 below, income elasticities are all positive, which
suggests that di¤erent outpatient antibiotic groups are normal goods.
Most price coe¢ cients are signicant at less than 1% with few exceptions, but
the demand for group 3 and group 4 seems to be positively related to their own
prices and negatively related to the price of other groups. Price elasticities will be
analysed later on in section 4.1 as we investigate complementary and substitution
e¤ects between antibiotic groups.
The impact of demographic variables and cultural aspects on the demand share
of all the four antibiotic groups is plausible but coe¢ cients are not highly signicant.
The age class 26 59 (POP3) is the baseline category. The proportion of individuals
over 74 years of age (POP5) reects some health considerations. The coe¢ cient
is positive and signicant at less than 10% for antibiotic group 3, whereas it is
negative and signicant at less than 1% for antibiotic group 4. This may suggest that
elderly people are more exposed to the risk of severe infections in the community
as compared to other individuals and these infections imply greater health risks.
Indeed, antibiotics in group 3 (3rd generation of cephalosporins and quinolones)
are commonly used for severe cases. The literature on the determinants of health
care expenditure indicates that the increasing prevalence of chronic health problems
associated with aging may cause an increase in the utilization of health care services
(Di Matteo and Di Matteo, 1998; Di Matteo and Grootendorst, 2002). We argue that
the share of antibiotics for more severe infections may increase with the proportion
of elderly patients in the community. Our result is also in accordance with ndings
by Mazzaglia et al. (1999), who suggested that cephalosporins are the antibiotics
most frequently prescribed for lower respiratory tract infections in adults, while
macrolides are the less prescribed ones.
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We did not nd clear evidence that a higher proportion of children (POP1) neg-
atively a¤ects the share of antibiotic group 1 (penicillins) and positively a¤ects the
share of macrolides. According to Otters et al. (2004), there has been a decrease in
the proportion of narrow-spectrum antibiotics prescribed for children between 1987
and 2001 in the Netherlands. By contrast, the proportion of macrolides increased
from 8% to 16%. Similarly, Schindler et al. (2004) showed that macrolides were
the most frequently prescribed antibiotics (48:1%) for respiratory infections among
children aged between 0 and 6 in Germany.
Areas with a French/Italian culture exhibit a signicantly lower consumption of
macrolides (group 4) and a higher consumption of 3rd generation cephalosporins and
quinolones (group 3) compared to areas with a German culture. Similar di¤erences
are observed at a larger scale across European countries. France and Italy, for
instance, use a relatively larger amount of 3rd generation cephalosporins as compared
to other European countries (Coenen et al. 2006).
The coe¢ cient of the incidence of infections signicantly increases with the share
of antibiotics in group 2 and negatively a¤ects antibiotics in group 3. The result
hypothesizes that epidemiological di¤erences are relevant in explaining variations in
the use of di¤erent types of antibiotics in the community. An increase in the spread
of community-acquired infections raises the share of narrow-spectrum antibiotics
rather than the share of the latest generation of antibiotics more suitable for severe
cases.
The study of the impact of bacterial resistance on the utilization of di¤erent
antibiotic groups may add some insights to the analysis of epidemiological aspects
although the interpretation needs a lot of carefulness. We did not nd evidences
to suggest that the share of di¤erent antibiotic groups is a¤ected by the degree of
bacterial susceptibility in the area, except for group 3. There may be some plausi-
ble explanations for this result. Since data are available for macro regions through
hospital guidelines, information may only partially become available to consumers.
Guidelines may not reach general practitioners and patients e¤ectively. The ex-
tent to which information is correctly understood and utilised cannot be assessed.
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Therefore, the interpretation of the relationship between bacterial resistance and
antibiotic demand in the following section could be undermined by this limitation.
Finally, we nd remarkable seasonal e¤ects on antibiotic shares. The baseline
season is represented by the fourth quarter, i.e. the autumn dummy (October,
November, December). The consumption of more expensive antibiotics (group 3
and 4) is higher in winter (1st quarter) and lower during the summer (3rd quarter).
This may connote higher risk aversion of doctors and patients in periods when
the incidence of infections is higher and severe infections occur more frequently.
Accordingly, the patients willingness to pay for drugs may rise with the perceived
risk of infection. By contrast, less expensive antibiotics, such as penicillins and early
generations of cephalosporins, are used less often during the rst quarter and more
often in the summer quarter.
4.1 Elasticities
Using the estimation results from Table 4 and applying the denitions derived in
section 2.2, we calculate the own-price, cross-price and expenditure elasticities of
the demand for di¤erent antibiotic groups. The gures are summarized in Table 5
and Table 6. Some important implications can be straightforwardly derived.22
[Table 5: about here]
Expenditure elasticities are positive for all antibiotic groups. The result may
suggest that antibiotics are normal goods and is in accordance with Baye et al.
(1997), who estimated that anti-infectives have positive income elasticity (around
1:3). More specically, Chaudhuri et al. (2003) observed positive expenditure elastic-
ities for di¤erent types of quinolones, ranging from 0:3 to 2:20. Since our expenditure
22As mentioned above, the demand system is estimated by assuming separability between the
consumption of antibiotics and other goods. The implication of this assumption is that the elastic-
ities are partial elasticities, for example they are conditional upon allocation of total expenditure
between antibiotics and other goods.
20
elasticities are very close to one, the consumption share of each group of antibiotics
remains constant as the amount spent on other groups changes. The evidence then
indicates that antibiotics in outpatient care can be denoted as necessities. As in-
come rises, the need for additional consumption of antibiotics is negligible, ceteris
paribus.
Grootendorst and Levine (2006) showed that pharmaceutical demand elasticities
depend on whether patients receive social assistance, or non-eligible patients have
private health insurance. Health insurance in Switzerland is mandatory for residents
and the same basic contract is o¤ered by competing private insurance companies.
The insurance premium varies according to a limited menu of deductibles. The
individuals income and health status partially a¤ect the selected level of deductible.
All uncompensated own-price elasticities have the expected negative sign and
vary substantially from  0:636 to  1:005. The comparison with the existing litera-
ture is not straightforward, although some similarities may be pointed out. Focusing
on anti-infectives, Baye et al. (1997) estimated uncompensated own-price elasticity
equal to  0:916. Ellison et al. (1997) found signicant and negative uncompen-
sated own-price elasticities for the four types of cephalosporins analysed. Looking at
quinolones only, Chaudhuri et al (2003) calculated a relatively high uncompensated
own-price elasticity, equal to  2:5 on average and ranging from  0:45 to  5:5.
[Table 6: about here]
Our estimates indicate that the demand for 3rd generation cephalosporins and
quinolones (group 3) and the demand for classic penicillins (group 1) are more
price elastic than the demand for penicillins amoxi/clav and 1st and 2nd generation
cephalosporins (group 2) and the demand for macrolides (group 4). It is worth
noticing that the highest own-price elasticities are found for the most expensive
antibiotic category (group 3) and the traditional and less frequently used antibiotics
(classic penicillins). The rationale may be that doctors and patients are more likely
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to increase or reduce the consumption of the latest generation of cephalosporins and
quinolones when their price changes, since this category of antibiotics is at least
partially used to reduce uncertainty on the severity of the infection and the risks
of bacterial resistance. On the other hand, they are less likely to leave commonly
used antibiotic therapies such as previous generations of cephalosporins, penicillins
and macrolides. Classic penicillins represent a traditional antibiotic therapy whose
comparative advantage has been substantially undermined by better alternatives.
Consequently, they may be quite sensitive to variations in relative prices.
As expected, the Hicksian own-price elasticities are smaller in magnitude com-
pared to the Marshallian elasticities. This indicates that the pure e¤ect of substitu-
tion is only partially compensated by the income e¤ect.
Substitution and complementary relationships among antibiotic groups are cap-
tured by the Allen elasticities summarized in Table 6. Positive values denote that
the two groups are substitutes. In our case, narrow spectrum antibiotics such as
penicillins amoxi/clav and early generations of cephalosporins (group 2) do not
appear to be good substitutes for antibiotics with a larger spectrum such as new
cephalosporins and quinolones (group 3). The rationale may be that old genera-
tions of cephalosporins are not perceived to be e¤ective against severe infections.
Moreover, newer generations are generally taken into account to overcome specic
problems of bacterial resistance encountered in the use of previous generations.
When the price of group 1 (classic penicillins) and group 4 (macrolides) increases,
doctors may prefer to switch to penicillins amoxi/clav and cephalosporins (group 2)
rather than to more e¤ective antibiotics such as newer generations of cephalosporins
and quinolones (group 3). Elasticities of substitution between groups 1 and 4 and
groups 2 and 3 are positive.
The Allens elasticity of substitution conrms that the demand for classic peni-
cillins follows the demand for macrolides when the price of the latter category
changes. The result may be associated with a certain degree of persistency in the
patients tastes. For instance, doctors argue that children have a preference for
macrolides rather than penicillins. This could imply that an increase in the price
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of macrolides is likely to induce a higher consumption of cephalosporins or newer
antibiotic components, rather than drive the utilization of classic penicillins upward,
ceteris paribus.
5 Conclusion
Antibiotic misuse and the cost of bacterial resistance are major threats to e¢ cient
treatment against community-acquired respiratory infections. The demand for an-
tibiotics has been investigated in studies by Ellison et al. (1997) and Chaudhuri et
al. (2003). Their focus is on specic market segments where antibiotic substances
constitute close therapeutic substitutes and are similar in terms of the impact of bac-
terial resistance. There are, however, arguments for considering a more extended
set of drugs. The major contribution of this study is the investigation of sources of
local variations in the use of di¤erent types of antibiotics in the community using an
econometric approach that takes into account the problem of spatial autocorrelation.
For this reason, we included a spatial lag on antibiotic consumption in the linear ap-
proximate demand system model to investigate antibiotic consumption across small
areas. Moreover, we added several socioeconomic determinants of antibiotic use in
the model, such as demographic and cultural characteristics of the population and
the patientshealth status. Therapeutic components are aggregated in four groups
suitable to dene, to the best of our knowledge, the doctors and patients choice
set in the treatment of community-acquired respiratory infections in Switzerland.
Estimations are carried out on 2002 quarterly data of dened daily doses per 1000
inhabitants (DID) available for 240 small areas.
The results lead us to the conclusion that the highest price demand elastici-
ties are observed for the 3rd generation cephalosporins and quinolones, which are
the newer and more expensive antibiotic category; and classic penicillins, which
are the most traditional and cheaper category. We found complementary e¤ects
between antibiotics with a relatively narrow spectrum (penicillins amoxi/clav and
cephalosporins 1st/2nd generations) and antibiotics with a relatively large spectrum
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(3rd generation cephalosporins and quinolones), and between classic penicillins and
macrolides. The demand elasticity suggests a good degree of substitution between
the other groups, for instance between penicillins amoxi/clav and cephalosporins
1st/2nd generations (group 2) and macrolides (group 4).
Looking at the impact of population characteristics, we observed that an in-
creasing proportion of elderly people positively a¤ects the proportion of new cepha-
losporins/quinolones (group 3) and reduces the proportion of macrolides used. The
rationale behind this may be that elderly people are more exposed to severe infec-
tions and to the risk of bacterial resistance. Italian- and French-speaking regions
are associated with a more substantial use of newer and more expensive antibiotics
(group 3) and a lower proportion of macrolides (group 4).
Because di¤erent groups of antibiotics are associated with di¤erent degrees of
bacterial resistance, variations in the practice of physicians and in the patientsat-
titudes are probably related to the stance towards the risk of bacterial resistance.
If bacterial resistance is developed for a certain class of antibiotics, no amount of
cross elasticity between this class and another class may persuade patients to pur-
chase or doctors to prescribe the ine¤ective class. Our approach makes an attempt
to take this aspect into account. Ignoring the possibility of awareness of bacterial
resistance by the general public would leave some ambiguities in our model. Our
analysis addresses the consumers willingness to trade o¤ a lower level of bacter-
ial resistance to a relatively higher price, since we tested the impact of available
information on bacterial resistance. Some evidence was found for one antibiotic
group (new cephalosporins/quinolones) only. This points at possible limitations of
our data. Firstly, data on bacterial resistance are available for macro regions only
rather than for local areas. Note, however, that relevant information on bacterial
resistance in Switzerland is meaningful at regional level. Although variations across
smaller areas are plausibly of little relevance and, consequently, not monitored, cur-
rent indicators are built on a limited number of sources. Secondly, information on
bacterial resistance may not be widely disseminated since it derives from guidelines
prepared by regional hospitals and are not always delivered to practitioners and
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consumers. Finally, our resistance indicators may not fully reect the e¤ectiveness
of antibiotic groups that combine di¤erent antibiotic substances. Clearly, we can-
not verify whether the dissemination of resistance data is e¤ective and patients are
fully aware of the resistance problem even though collected data are reliable and
resistance indicators are easy to understand since they are provided in the form of
simple ratios.
Despite limitations, the analysis helps to enlighten the impact of determinants
of variations in the use of di¤erent types of antibiotics in the community. Our nd-
ings indicates that health care policy makers may improve e¢ ciency in antibiotic
use by taking economic incentives into account. One example can be a more e¤ec-
tive dissemination of information on prices and the impact of bacterial resistance
to physicians and patients. The Swiss Sentinella on antimicrobial resistance relies
on a network of laboratories in the country and publishes resistance indicators on
the web. The collection of data and the provision to the Sentinella can be eased by
the implementation of a national monitoring centre, to be appointed by the federal
authority. The information provided could then be used by regional health author-
ities to prepare leaets and publish articles in newspapers targeted at the general
public and/or general practitioners. Finally, the dissemination of information could
be combined with another policy instrument like a regional tax/subsidy system that
induces the use of antibiotic categories less a¤ected by resistance problems or an-
tibiotics (generally those with narrow spectrum) that are less likely to contribute to
the resistance problem.
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Antibiotic group Description of main active ingredients
Group 1: Penicillins (classic) Penicillin V, amoxicillin, ampicillin
Group 2: Penicillins (amoxi/clav) and Clavucanic acid/amoxicillin, cefaclor,
1st 2nd generation cexime, cefadroxil, cefetamet pivoxil,
cephalosporins cefprozil, cefuroxime axetil
Group 3: 3rd generation cephalosporins Ceftibuten, cefpodoxime proxetil,
and quinolones moxioxacin, levooxacin
Group 4: Macrolides Erytromycin, clarithromycin,
roxithromycin, azithromycin
Table 1: Antibiotic groups used in the treatment of respiratory infections.
Min Mean SD Max
Expenditure share
Group 1 0.018 0.093 0.029 0.233
Group 2 0.149 0.463 0.069 0.704
Group 3 0 0.141 0.056 0.430
Group 4 0.154 0.303 0.073 0.787
Price
Group 1 0.974 1.589 0.212 2.639
Group 2 2.331 3.340 0.220 4.018
Group 3 4.974 5.935 0.291 7.451
Group 4 3.614 4.787 0.344 6.086
Table 2: Summary statistics of budget shares and prices for the four groups of
antibiotics.
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Variable Description Min Mean Max
x=P Income per capita dened in CHF 15,422 23,465 51,446
POP1 Population under 14/total population 0.088 0.166 0.218
POP2 Population between 15 and 25/total population 0.069 0.125 0.185
POP3 Population between 26 and 59/total population 0.423 0.495 0.638
POP4 Population between 60 and 74/total population 0.095 0.136 0.249
POP5 Population over 74/total population 0.034 0.077 0.139
INF Incidence of common gastrointestinal infections 91.9 114.7 187.7
(Salmonella and Campylobacter) in 100,000 inhab.
INF2 Incidence of common respiratory infections 2 64.98 144
(Streptococcus) in 100,000 inhabitants
DLAT Areas with a Latin culture - 0.437 -
RES Resistance indicator (pneumococcal susceptibility) West Mid East
Group 1 76 90.4 93.2
Group 2 76 100 96.1
Group 3 83 90.9 87.6
Group 4 100 97.7 69.5
Table 3: Variables notation and summary statistics.
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Group 2: Group 3: Group 4:
Penicillins (amoxi/clav) 3rd generation Macrolides
and 1st - 2nd generations cephalosporins
cephalosporins and quinolones
Obs. 720 720 720
R2 0.358 0.402 0.479
Coe¤. S.E. Coe¤. S.E. Coe¤. S.E.
Constant 0.2327 0.089 0.1514 0.068 0.0716 0.111
DID i 0.6001 0.035 0.6083 0.040 0.5950 0.036
P1 0.1502 0.028 -0.0838 0.021 -0.0674 0.021
P2 0.0009 0.011 0.0521 0.010 -0.0512 0.010
P3 -0.0838 0.021 0.0120 0.025 0.0126 0.019
P4 -0.0673 0.021 0.0126 0.019 0.1060 0.025
x=P 0.0001 0.004 -0.0016 0.003 -0.0041 0.004
POP1 -0.0059 0.029 0.0076 0.023 0.0145 0.025
POP2 0.0343 0.027 0.0017 0.022 -0.0395 0.024
POP4 0.0004 0.017 -0.0014 0.014 0.0221 0.015
POP5 0.0134 0.010 0.0159 0.008 -0.0403 0.009
INF 0.0106 0.004 -0.0068 0.004 -0.0046 0.004
INF2 -0.0002 0.002 -0.0017 0.002 -0.0021 0.002
DLAT 0.0038 0.007 0.0121 0.005 -0.0147 0.007
RES 0.0004 0.000 0.0002 0.000 -0.0008 0.001
DT2 -0.0011 0.005 0.0042 0.004 -0.0145 0.004
DT3 0.0129 0.005 -0.0020 0.004 -0.0200 0.004
 signicant at 10%,  signicant at 5%,  signicant at 1%,  signicant at 0.1%
Table 4: Parameter estimates for the restricted linear approximate AIDS model of
antibiotic groups.
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Uncompensated Compensated Expenditure
price elasticities price elasticities elasticities
Classic -1.005 -0.903 1.050
penicillins
Penicillins (amoxi/clav)
and 1st - 2nd generation -0.683 -0.209 1
cephalosporins
3rd generation
cephalosporins -1 -0.863 1
and quinolones
Macrolides -0.636 -0.345 1
Table 5: Price elasticities and expenditure elasticities evaluated at the sample mean.
Classic Penicillins 3rd generation Macrolides
penicillins (amoxi/clav) cephalosporins
and 1st - 2nd gen. and quinolones
cephalosporins
Classic
penicillins - 1 4.860 -0.808
Penicillins
(amoxi/clav) - - -0.286 0.512
and 1st - 2nd gen.
cephalosporins
3rd generation
cephalosporins - - - 1
and quinolones
Table 6: Allen elasticity of substitution between two groups of antibiotics.
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